Genetic dilated cardiomyopathy

Article written and reviewed by Dr Luca Moretti

Genetic dilated cardiomyopathy is caused, or substantially predisposed, by an inherited or de novo variant capable of impairing myocardial structure, function or electrical stability. Etiology is not defined by the mere presence of a rare variant: gene-disease validity, a coherent mechanism, variant classification and concordance with the phenotype are required. A molecular diagnosis arises from integration, not from automatic reading of a gene panel.

A substantial proportion of DCM has a monogenic basis, with higher yield in families with multiple affected members, early-onset cases and arrhythmic or conduction phenotypes. Even apparently sporadic patients may carry a pathogenic variant because of incomplete penetrance, a de novo variant or unrecognized disease in relatives. A negative family history lowers pretest probability but does not exclude a genetic origin.

Most forms follow autosomal dominant inheritance, but recessive, X-linked and mitochondrial conditions also occur. Age-dependent penetrance and variable expressivity mean that the same variant may cause early arrhythmias in one relative, late heart failure in another and no evident phenotype in a third. Intrafamilial variability prevents the proband’s prognosis from being mechanically transferred to healthy carriers.

A genetic result may confirm etiology, modify arrhythmic assessment, guide surveillance and enable cascade testing. It may also clarify neuromuscular disease, guide reproductive counseling and help prevent adverse exposures in vulnerable individuals. The clinical value of testing therefore depends on the decision it makes possible, not simply on the percentage of positive results.

Genetic architecture also includes polygenic and environmental modifiers. Alcohol, pregnancy, myocarditis, chemotherapy and exercise load may bring forward or amplify the phenotype in susceptible carriers without being either irrelevant or necessarily sufficient on their own. The multiple-hit model explains why an apparently acquired cause should not terminate family evaluation.

Genetic architecture and disease mechanisms

TTN encodes titin, a giant sarcomeric protein that links the Z disc to the M line and contributes to elasticity, assembly and signaling. Truncating variants in highly expressed cardiac exons are a common cause of DCM, whereas many truncating variants in sparsely used regions have different significance. TTN interpretation requires genomic position, percentage spliced in within the heart and population frequency, not a simple predicted loss-of-function label.

LMNA encodes nuclear lamins that support the nuclear envelope, chromatin organization and stress responses. LMNA cardiomyopathy often presents with atrioventricular block and atrial or ventricular arrhythmias before severe dilation. The laminopathy phenotype carries a risk of potentially lethal arrhythmias that may exceed what ejection fraction suggests and therefore requires particular attention to device selection.

FLNC encodes filamin C, a cytoskeletal and Z-disc protein. Truncating variants are associated with dilated or nondilated phenotypes with fibrosis, ventricular arrhythmias and sudden-death risk; other variant classes may cause myopathies or hypertrophic cardiomyopathy. The variant-specific mechanism is essential because not every FLNC change confers the same risk.

DSP and other desmosomal genes connect cardiomyocytes and transmit force. Desmoplakin variants may produce left ventricular subepicardial scar, myocarditis-like episodes with pain and troponin elevation, and arrhythmias before dilation. DSP cardiomyopathy shows how the boundaries among DCM, arrhythmogenic cardiomyopathy and myocarditis may be descriptive rather than biologically separate.

RBM20 regulates splicing of numerous cardiac transcripts, including titin. Variants clustered in critical regions cause often early-onset DCM, arrhythmias and progression; not all variants in the gene are equivalent. The RBM20 domain and family segregation help distinguish a causal variant from a rare finding without sufficient evidence.

PLN encodes phospholamban, a regulator of calcium reuptake into the sarcoplasmic reticulum. Some founder variants, such as p.Arg14del in specific populations, cause an arrhythmogenic phenotype with fibrosis and variable dysfunction. PLN disease requires variant- and population-specific interpretation, avoiding attribution of the risk observed for a founder mutation to every substitution in the same gene.

BAG3, DES, SCN5A, MYH7, TNNT2, TPM1 and other genes with established evidence act on proteostasis, intermediate filaments, ion channels and the sarcomere. Each produces different combinations of pump failure, rhythm abnormalities and extracardiac manifestations. Molecular heterogeneity justifies curated panels and deep phenotyping, but not indiscriminate inclusion of hundreds of genes with weak associations.

Mitochondrial variants, dystrophinopathies, syndromic laminopathies and metabolic diseases may present as DCM, particularly in childhood. Weakness, elevated creatine kinase, contractures, hearing loss, diabetes or neuropathy are important clues. The extracardiac phenotype guides testing beyond the standard cardiac panel and enables a diagnosis that changes systemic and family management.

The presence of two pathogenic variants or a polygenic background may increase severity, but oligogenicity should not be invoked to explain every discordance. Age, sex, exposures and biological stochasticity already create wide variability. Genetic modifiers are a promising research field but currently seldom have sufficiently robust individual interpretation for clinical decisions.

Electrical phenotypes and genotype-phenotype correlations

In genetic DCM, electrical abnormalities may precede pump dysfunction. Atrioventricular block, early atrial fibrillation, nonsustained ventricular tachycardia or ectopy disproportionate to ventricular function suggest an arrhythmogenic genotype. An early electrical phenotype should prompt monitoring and genetic evaluation even when the chamber does not yet meet classic dilation criteria.

LMNA is paradigmatic: conduction disease and atrial arrhythmias may appear years before ventricular dysfunction. Sex, variant type, nonsustained ventricular tachycardia, conduction block and ejection fraction contribute to risk estimation. LMNA risk is not a binary property of the gene but a probability built from variant and phenotype and should be discussed with its limitations and competing risks.

Truncating FLNC variants and some DSP variants are associated with scar and arrhythmias despite only moderately reduced or preserved function. CMR may show subepicardial or ring-like LGE and identify a substrate before dilation. Discordance between LGE and ejection fraction signals that systolic thresholds alone underestimate electrical vulnerability.

TTN-related DCM often shows good capacity for reverse remodeling with therapy, but that does not make it benign. Arrhythmias, alcohol exposure, pregnancy or chemotherapy may unmask the phenotype, and recovery does not remove the variant. TTN plasticity supports aggressive treatment and control of stressors without absolute reassurance after normalization.

RBM20 may combine young onset, severe dilation and arrhythmias. The specific variant region and family history influence the plausibility of risk, while small sample sizes limit estimates. Genotype-specific information should be used to intensify surveillance and discussion, not to promise certain prediction.

SCN5A may cause DCM associated with atrial arrhythmias, conduction abnormalities or ectopy; in some families, arrhythmia suppression improves function, suggesting an electromechanical link. SCN5A pleiotropy requires searching for channelopathy phenotypes and avoiding interpretation of dilation as a purely structural effect.

DES and LMNA may involve skeletal muscle, whereas X-linked dystrophinopathies mainly affect males and may manifest in the heart before or after myopathy. Creatine kinase, neurologic examination and maternal family history are therefore part of genetic cardiology. Neuromuscular manifestations change anesthesia, rehabilitation, respiratory care and counseling of relatives.

A genotype-phenotype correlation is not a rule without exceptions. Relatives with the same variant differ in age at onset, arrhythmia prevalence and response, and reference cohorts may be enriched for severe forms. Contextual penetrance requires presenting the gene as a risk modifier rather than a predetermined fate.

Indication, performance and interpretation of genetic testing

Testing is recommended when it can confirm diagnosis, guide prognosis or treatment, inform reproductive choices or enable cascade testing. Probability increases with a family history, young onset, conduction abnormalities, characteristic LGE or extracardiac signs. The clinical indication should not be limited to large families because the principal benefit may be identifying relatives at risk.

The ideal proband is a clearly affected relative, preferably with early onset or an informative phenotype. Testing a healthy person first may yield an uninterpretable negative result because the familial variant is unknown. The proband-first strategy maximizes yield and allows simpler targeted testing in relatives.

Pretest counseling explains possible result categories, limitations, incidental findings, potential insurance or occupational implications according to applicable law, and the right not to know. It also explores who will communicate the result to the family. Genetic consent is an informational process, not a technical signature added to a laboratory request.

Panels should prioritize genes with definitive, strong or moderate evidence and include methods for deletions, duplications and relevant variants not captured by sequencing alone. A larger panel is not necessarily more clinically sensitive because it increases uncertain findings. Panel curation is part of diagnostic quality.

Variants are classified as pathogenic, likely pathogenic, uncertain, likely benign or benign using population frequency, functional evidence, segregation, clinical observations and predictions. Classification concerns the variant in relation to disease, not severity in a carrier. A pathogenic variant may have incomplete penetrance and does not permit prediction of age at onset or disease course without additional data.

A VUS is not a positive result. It should not be used to release variant-negative relatives from follow-up or to justify an ICD, prenatal diagnosis or other irreversible decisions. VUS management may include segregation studies in affected relatives and periodic reassessment, while decisions remain anchored to phenotype.

A negative test does not exclude a genetic cause: the gene may be unknown, the variant undetectable, the mechanism complex or interpretation still immature. In a clinically affected family, relatives continue to undergo screening. An uninformative negative is conceptually different from a relative testing negative for a pathogenic variant already identified in the proband.

Reclassification is inevitable as evidence accumulates. The laboratory, clinician and patient should have a pathway for updating results, especially for variants initially classified as uncertain. Report maintenance is part of long-term care because a new classification may change surveillance across an entire family.

Family screening and reproductive counseling

First-degree relatives undergo history, ECG and imaging even before the genetic result because they may have silent disease requiring treatment. Starting age and intervals depend on gene, family history and stage of life. Clinical screening looks for electrical disease, dysfunction and scar, not only overt dilation.

When a familial pathogenic variant is known, cascade testing identifies who inherited it. Noncarriers can generally be discharged from disease-specific surveillance if the variant convincingly explains the family and no other causes are present. Targeted family testing avoids repeated broad panels and reduces incidental variants.

Genotype-positive, phenotype-negative carriers receive follow-up without automatic DCM treatment. Blood pressure, exposures, activity, pregnancy and symptoms are discussed, while ECG and imaging are repeated at intervals. The prephenotypic phase requires balance between prevention and medicalization, recognizing that many carriers remain well for a long time.

CMR and Holter monitoring are particularly useful in genes associated with scar or early arrhythmias, even when echocardiography is normal. Selection avoids identical protocols for everyone. Gene-guided surveillance is more rational when supported by evidence but does not replace clinical assessment of family-specific features.

In minors, predictive testing is appropriate when the result changes surveillance or prevention during childhood. Parental consent and the child’s assent are adapted to maturity, and the result is revisited during transition. Pediatric genetics protects medical benefit and future autonomy at the same time.

Autosomal dominant inheritance generally means a 50% probability of transmission in each pregnancy, but not a 50% probability of severe disease. Penetrance and expressivity remain uncertain. Reproductive counseling distinguishes inheritance, phenotype development and severity and presents natural conception, prenatal diagnosis or preimplantation testing without coercively steering the choice.

Pregnancy may unmask DCM in some carriers and warrants preconception assessment based on ventricular function, LGE, gene and history. An asymptomatic carrier does not automatically have a contraindication but may require closer follow-up. Maternal reproductive risk is separate from genetic risk to the child and should be communicated as such.

Intra-family communication may encounter conflict, distance or refusal. The team provides clear letters and support while respecting confidentiality and applicable law. Shared responsibility aims to inform relatives without turning the proband into the sole manager of complex and potentially emotional information.

Arrhythmic prevention, treatment and future directions

Heart failure therapy follows the phenotype and does not wait for genetic results. An ARNI or renin-angiotensin system inhibitor, beta-blocker, mineralocorticoid receptor antagonist and SGLT2 inhibitor are introduced when indicated, together with decongestion. The genotype does not replace proven therapy but may change its urgency and surveillance.

The ICD decision considers ejection fraction, symptoms, arrhythmias, LGE, gene and life expectancy. In LMNA disease and other high-risk genotypes, prevention may be discussed before ejection fraction reaches conventional thresholds. The genotype-guided threshold remains a shared decision because devices have cumulative complications and risk estimates are imperfect.

If a laminopathy requires pacing for block, a system with defibrillation capability may be preferred when arrhythmic risk is significant, avoiding a later upgrade. Need for resynchronization and venous anatomy also enter the choice. Device planning considers the expected disease course, not only the bradycardia present today.

Modifiable exposures deserve particular attention. Reducing alcohol, avoiding stimulants, monitoring cardiotoxic treatments and planning pregnancy may reduce the risk of phenotypic expression or recurrence without eliminating the variant. Environmental prevention is an immediate application of genetics and does not require waiting for molecular therapies.

Functional recovery may be frequent in some TTN-related DCM and after removal of a trigger, but it does not justify treatment withdrawal. Genetic vulnerability persists and new stressors may reactivate disease. Genetic remission requires tolerated therapy and follow-up, with particular caution when scar or previous arrhythmias are present.

Gene silencing, editing, gene replacement and splicing modulation are under investigation but must overcome delivery, dose, immunity and specificity challenges. Preclinical results are not equivalent to clinical availability. Future gene therapy should not be presented as a current alternative to ICDs, drugs or transplantation.

International registries and controlled data sharing improve penetrance estimates and classification of rare variants. Data collection should include unaffected relatives, otherwise risk appears artificially high. Unselected evidence is essential for turning genetic associations into reliable decisions.

Genetic dilated cardiomyopathy is therefore a familial and longitudinal diagnosis. The report acquires meaning only when connected to myocardial history, arrhythmias, exposures and relatives. Precision medicine does not consist of accumulating genes but of reducing uncertainty and preventing events through rigorously interpreted information.

Genes, variants and selected interpretive scenarios

TTN truncating variants are the most common monogenic cause, but interpretation depends on location in cardiac-expressed exons and context. Truncating variants also occur in controls, and not every loss-of-function change has the same effect. Titin cardiomyopathy therefore requires transcript annotation, segregation and phenotypic compatibility, not merely the word truncating in the report.

TTN carriers may develop disease after pregnancy, alcohol, chemotherapy or other stresses, illustrating environmentally modified penetrance. Identification does not allow a mathematical share to be assigned to each factor but signals vulnerable reserve. Gene-environment interaction explains why removing the exposure remains necessary even when a causal variant is present.

LMNA links DCM with conduction block, sinus node disease and ventricular arrhythmias that may precede severe reduction in ejection fraction. The ICD decision integrates sex, variant type, atrioventricular block, nonsustained ventricular tachycardia and function, using validated tools without turning them into automatism. The laminopathy phenotype requires earlier electrical vigilance than generic DCM.

FLNC and DSP may produce left-sided or biventricular phenotypes with fibrosis and arrhythmias disproportionate to dilation. Episodes of pain and troponin elevation may mimic myocarditis and represent inflammatory phases of cardiomyopathy. Left-sided arrhythmogenic forms show the limitations of historical boundaries between DCM and arrhythmogenic cardiomyopathy.

RBM20 alters splicing of numerous cardiac transcripts and is associated with relatively early onset and substantial arrhythmic risk in some families. PLN, particularly in populations carrying founder variants, may produce a dilated-arrhythmogenic overlap. Gene specificity modifies surveillance and counseling, but the strength of associations must be distinguished from precise estimates that are not yet generalizable.

BAG3, DES and cytoskeletal genes may associate cardiomyopathy with muscular or neurologic manifestations, sometimes subtle. A normal CK does not exclude every genetic myopathy, and targeted neuromuscular examination may precede more specific testing. The extracardiac phenotype narrows interpretation and guides care beyond the heart.

Deletions, duplications and other structural variants may not be detected by all panels with the same sensitivity. Inadequate coverage, repetitive regions and mosaicism also limit testing. Technical negativity must be interpreted with knowledge of methodology and limitations, especially when the pedigree strongly suggests inheritance.

Germline or somatic mosaicism may explain unexpected recurrences or an apparently negative parent, but it is not routinely sought in every family. A de novo variant in the proband reduces but does not eliminate risk to siblings and has different implications for offspring. Recurrence risk is communicated with ranges and uncertainty, avoiding false precision.

Many databases and historical cohorts disproportionately represent European populations, increasing the number of rare variants that are difficult to classify in other ancestries. Population frequency and clinical observations must be updated with diverse data. Genomic equity is a component of accuracy because an uninformative VUS may result from gaps in the reference data rather than the biology of the family.

Reclassification is a clinical act, not merely an informatics task. The laboratory, center and family should have a pathway to receive updates, reassess segregation and change screening only when new evidence justifies it. Maintenance of the result accompanies the patient for years and prevents an outdated report from continuing to govern decisions that are no longer valid.